title: Effects of Iloprost and pentoxifylline on renal ischemia-reperfusion in rabbit model.
abstract: OBJECTIVE
  In ischemia-reperfusion, Iloprost decreases neutrophil activation and aggregation besides inhibition of oxygen-free radical production. Pentoxifylline (Ptx) attenuates reperfusion-associated membrane injury and tissue edema, suppresses leukocyte adhesion and improves hindlimb blood flow during the reperfusion period. The primary hypothesis in this study was that Iloprost could present better protection than pentoxyfillin on renal ischemia-reperfusion in rabbit model.
  
  
  METHODS
  Forty rabbits were grouped into four. Iloprost was continuously infused starting half an hour before the reperfusion after 2 hours ischemia and during the 4 hours reperfusion period in Group 1 whereas the Group 2 was treated with pentoxyfillin. Group 3 was the control group which didn't receive any medication. Forth group was sham group. Renal tissues were histologically and biochemically evaluated.
  
  
  RESULTS
  The histologic scores were obtained according to presence of tubuler necrosis and atrophy, regenerative atypia, hydropic degeneration (Group 1 vs Group 3; p<0.001, Group 2 vs Group 3; p = 0.001, Group 1 vs Group 2; p = 0.331). Malondialdehyde levels of the medicated groups were 109 +/- 11 nmol/gr tissue in Group 1, 119 +/- 15 nmol / gr tissue in Group 2 and 132 +/- 14 nmol / gr tissue in Group 3 (Group 1 vs Group 2; p = 0.130, Group 1 vs Group 3, p = 0.002, Group 2 vs Group 3; p = 0.045). Malondialdehyde levels and histologic scores of all of the groups were significantly different from the sham group.
  
  
  CONCLUSIONS
  Iloprost and pentoxyfillin reduced renal ischemia-reperfusion injury in rabbit model. There was not a significant difference between these two medications.
authors.affiliation: Ataturk Training and Research Hospital, Department of Cardiovascular Surgery, Izmir, Turkey. bilginemrecan@yahoo.com
authors.forename: B
authors.initials: B
authors.lastname: Emrecan
authors.forename: E
authors.initials: E
authors.lastname: Tulukoglu
authors.forename: S
authors.initials: S
authors.lastname: Bozok
authors.forename: M
authors.initials: M
authors.lastname: Kestelli
authors.forename: G
authors.initials: G
authors.lastname: Onem
authors.forename: A
authors.initials: A
authors.lastname: Küpelioglu
authors.forename: S
authors.initials: S
authors.lastname: Yagdi
authors.forename: A
authors.initials: A
authors.lastname: Gürbüz
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D016285:Iloprost / Q000627:therapeutic use*; D007668:Kidney / Q000098:blood supply* / Q000473:pathology; D007672:Kidney Cortex / Q000378:metabolism; D007684:Kidney Tubules / Q000473:pathology; D015227:Lipid Peroxidation; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010431:Pentoxifylline / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011817:Rabbits; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D008315:Malondialdehyde; D016285:Iloprost; D010431:Pentoxifylline